Related Experiment Video
Updated: Jun 28, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Dendritic cell vaccines for the treatment of prostate cancer
1Department of Surgery, Division of Urology, Penn Presbyterian Medical Center, Philadelphia, PA 19194, USA.
Abstract:
Advanced prostate cancer remains a disease with few options beyond palliation. Over the past few decades, our understanding of immunology has led to the development of novel therapies for the treatment of many malignancies, including prostate cancer. These generally aim to induce T-cell responses against tumor specific antigens to both reduce tumor mass and potentially avoid relapse. One promising technique is to use autologous dendritic cells, the most potent antigen presenting cell. These can be loaded ex vivo with a given antigen and subsequently injected back into the patient to stimulate the desired effect. Recent trials using these techniques have shown promise in extending survival in patients with prostate cancer. This review will discuss relevant biology behind dendritic cell therapy and highlight the key trials found in the literature.
Insights
Advanced prostate cancer treatment is limited. Dendritic cell therapy, using potent antigen-presenting cells, shows promise in clinical trials by stimulating T-cell responses to reduce tumor mass and extend survival.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Background:
- Advanced prostate cancer has limited therapeutic options, often restricted to palliative care.
- Advances in immunology have spurred the development of novel cancer treatments, including immunotherapies.
- Dendritic cells are highly effective antigen-presenting cells crucial for initiating T-cell responses against tumors.
Purpose of the Study:
- To review the biological principles of dendritic cell therapy for cancer.
- To highlight key clinical trials investigating dendritic cell therapy in prostate cancer.
- To discuss the potential of dendritic cell therapy in managing advanced prostate cancer.
Main Methods:
- Review of scientific literature focusing on dendritic cell biology and immunotherapy.
- Analysis of clinical trial data for dendritic cell-based treatments in prostate cancer.
- Discussion of ex vivo antigen loading and in vivo administration of dendritic cells.
Main Results:
- Dendritic cell therapy aims to induce T-cell responses against tumor-specific antigens.
- Ex vivo loaded autologous dendritic cells can be administered to patients to stimulate anti-tumor immunity.
- Recent clinical trials indicate that dendritic cell therapy may prolong survival in prostate cancer patients.
Conclusions:
- Dendritic cell therapy represents a promising immunotherapeutic strategy for advanced prostate cancer.
- Further research and clinical trials are warranted to optimize dendritic cell therapy protocols.
- This approach offers potential for reducing tumor burden and preventing relapse in prostate cancer patients.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy